David Lacey
Directeur/Membre du Conseil chez NURIX THERAPEUTICS, INC.
Fortune : 2 M $ au 30/06/2024
Profil
David L.
Lacey is currently an Independent Director at Atreca, Inc., an Independent Non-Executive Director at Inbiomotion SL, an Independent Director at Arcus Biosciences, Inc., a Director at Nurix Therapeutics, Inc., and a Venture Partner at Ysios Capital Partners SGEIC SA. Previously, he served as an Independent Non-Executive Director at argenx SE from 2014 to 2021, a Director at Rainier Therapeutics, Inc., an Independent Director at Unity Biotechnology, Inc. from 2018 to 2020, and a Senior Vice President-Discovery Research at Amgen, Inc. from 1994 to 2011.
He also held positions at The University of Colorado as an Associate and at Jewish Hospital as an Assistant Professor.
Dr. Lacey obtained his undergraduate degree from The University of Colorado in 1980 and his doctorate from The University of Colorado School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARCUS BIOSCIENCES, INC.
0,06% | 06/06/2024 | 57 652 ( 0,06% ) | 878 040 $ | 30/06/2024 |
NURIX THERAPEUTICS, INC.
0,05% | 20/05/2024 | 33 333 ( 0,05% ) | 695 660 $ | 30/06/2024 |
Postes actifs de David Lacey
| Sociétés | Poste | Début |
|---|---|---|
| NURIX THERAPEUTICS, INC. | Directeur/Membre du Conseil | 20/05/2024 |
| ATRECA, INC. | Directeur/Membre du Conseil | 31/05/2016 |
| ARCUS BIOSCIENCES, INC. | Directeur/Membre du Conseil | 21/05/2020 |
Inbiomotion SL
 Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Directeur/Membre du Conseil | 01/12/2012 |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Private Equity Investor | 01/06/2020 |
Anciens postes connus de David Lacey
| Sociétés | Poste | Fin |
|---|---|---|
| ARGENX SE | Directeur/Membre du Conseil | 11/05/2021 |
| UNITY BIOTECHNOLOGY, INC. | Directeur/Membre du Conseil | 14/12/2020 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2011 |
| The University of Colorado | Corporate Officer/Principal | - |
| ░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de David Lacey
| The University of Colorado | Undergraduate Degree |
| The University of Colorado School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| ARGENX SE | Health Technology |
| AMGEN INC. | Health Technology |
| NURIX THERAPEUTICS, INC. | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Inbiomotion SL
Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Health Technology |
Atreca, Inc.
 Atreca, Inc. BiotechnologyHealth Technology Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman on June 11, 2010 and is headquartered in San Carlos, CA. | Health Technology |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Health Technology |
Jewish Hospital
 Jewish Hospital Hospital/Nursing ManagementHealth Services Part of Community Health Systems, Inc., Jewish Hospital is a hospital. The company is based in Cincinnati, OH. Jewish Hospital was acquired by Mercy Health Partners, Inc. (Pennsylvania), a NPO of Community Health Systems, Inc. from Jewish Foundation of Cincinnati on March 01, 2010 for $180 million. | Health Services |
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Finance |
